Atlas Trials

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Clinical trial NCT05613413 · RECRUITING

Trial details

NCT number
NCT05613413
Sponsor
University of Illinois at Chicago
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Squamous Non-Small Cell Lung Carcinoma
Start date
2022-12-28
Primary completion
2028-09-01
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.